Precision, long-chain DNA.
Remarkable efficiency.
No compromises.

Write the Future

By the year 2030, production utilizing biotechnology is expected to comprise 2.7% of global gross domestic product, an amount valued at approximately 1.7 trillion USD. This trend is not limited to the the medical and food industries, however―the use of biotechnology is anticipated to become commonplace in manufacturing and energy production as well. As mankind faces a plethora of environmental problems and critical issues of a global scale, biotechnology is poised to make enormous contributions towards humanity’s shared future. Thanks to recent advances in synthetic biology, the age is fast approaching where mankind can―through the synthesis of DNA―engineer an unlimited number of biological mechanisms.

At the core of synthetic biology is the ability to “read” and “write” DNA, which encodes the information by which biological processes take place. By utilizing Synplogen’s proprietary gene synthesis process, we hope to contribute to the richer future promised by synthetic biology and biotechnology.

A new approach

Some DNA is simply too long and complicated to be synthesized effectively using current methods, and attempting to do so typically results in the loss of important information or functionality. Synplogen delivers DNA exactly as the customer has ordered, at reasonable costs even for DNA up to 100 kbp in length or more.



The microbial production process involved in manufacturing products such as medicine, cosmetics, biomaterials, or commodity chemicals sometimes requires synthesizing genetic circuits consisting of dozens of genes. Cost-effective and combinatorial optimization of these gene clusters enables high-throughput screening of novel, more productive strains.

Medical treatment & drug development

Effective gene therapy for humans is quickly moving from the realm of science fiction to the real world. DNA applications for gene therapy often require long chains of tens of thousands of base pairs, such as optimized viral vectors with higher transduction efficiencies and lower immunogenicity. Animal disease model research is another exciting field for DNA assembly technologies.


Synplogen develops competitive DNA synthesis technologies. Two of our technologies highlighted below allow for high-throughput DNA synthesis at remarkable lengths and levels of efficiency. Synplogen’s initial technologies are the result of more than ten years of intense research and development that began at Kōbe University and which combines cutting-edge genetic engineering approaches with information science and robotics.


  • Long-chain DNA synthesis

    Synthesis of long-chain DNA (up to 100 kbp)

  • Combinatorial DNA library synthesis

    Synthesis of DNA libraries using combinatorial design

  • Support for developing production-use microbes

    Assistance with the design and synthesis of gene clusters for the development of production-use microorganisms

Precision, long-chain DNA.
Remarkable efficiency. No compromises.



Company Name Synplogen Co., Ltd.
Address HQ: 1-1 Rokkodaicho, Nada-ku Kobe-shi, Hyogo, 657-0013, Japan
Branch office: 234-1 Mizukami Kakuganji Tsuruoka-shi, Yamagata, 997-0052, Japan
Founded February 21, 2017
Paid-in Capital ¥1.118 billion (Incl. capital reserves)
Board of Directors
  • CEO        Junichi Sugahara, PhD

    Junichi Sugahara graduated with a B.S. from the Keio University Faculty of Environmental Information in 2007, and subsequently received a doctorate in bioinformatics from the university’s Graduate School of Media and Governance in 2011. An initial founder of Spiber, Junichi has served as a company director since its establishment in 2007, and Representative Director of Synplogen from September 2018.

  • Director       Akihiko Kondo, PhD

    After graduating from the Kyoto University Undergraduate School of Industrial Chemistry in 1983, Akihito Kondo received a doctorate from the university’s Department of Chemical Engineering in 1988. Beginning in 2003, he joined Kobe University’s Faculty of Engineering, where he later worked as a professor. From 2016 to present, Akihito has served as the head of the Kobe University Graduate School of Science, Technology and Innovation. Akihito founded Synplogen Co., Ltd. in February 2017, and currently serves as a company director.
    Academic profile:

  • Director       Kenji Tsuge, PhD

    Kenji Tsuge graduated from the Saitama University Department of Applied Chemistry in 1993. He received his doctorate from the Tokyo Institute of Technology’s Interdisciplinary Graduate School of Science and Engineering in 1998. After a fellowship at the Mitsubishi Kagaku Institute of Life Sciences, Kenji worked as an senior lecturer at the Institute for Advanced Biosciences, Keio University. Since 2016, he has served as an associate professor at the Kobe University Graduate School of Science, Technology and Innovation. Inventor of the OGAB method, Kenji is one of Synplogen’s founders and has served as company director since the company’s creation in February 2017.

  • Director       Kazuhiko Yamanoto

    Kazuhiko Yamamoto graduated in 1988 from the Hitotsubashi University Faculty of Commerce and Management. He has worked at Sumitomo Electric Industries, the Nomura Research Institute, and various venture companies in accounting and strategic management positions. Kazuhiko founded and served as the representative director of an independent venture capital firm from 1998 until 2016. A specialist in development-stage venture investment, Kazuhiko is also an authority on corporate financing, and has worked as a consultant on topics such as mergers and acquisitions and financial strategy. Since early 2016 Kazuhiko has served as a professor at the Kobe University Graduate School of Science, Technology and Innovation. He became a director of Synplogen in September 2018.

  • Director       Yoshihiro Oshima

    Yoshihiro Oshima graduated from the Keio University Faculty of Law in 2007. The same year, he joined the Deutsche Bank Group, where he served as an advisor on cross-border mergers and acquisitions. Yoshihiro joined Spiber Inc. in 2018, and subsequently became a director of Synplogen in September 2018.

  • Director       Daniel Meyer

    After spending part of his undergraduate degree studying abroad at Temple University’s Tokyo campus, Daniel Meyer graduated from Seattle Pacific University College of Business in 2010 with a degree in International Business. Daniel joined Spiber Inc. in 2015, where he currently oversees business development and fundraising projects. He became a director of Synplogen in September 2018.